|Bid||0.3150 x N/A|
|Ask||0.3200 x N/A|
|Day's Range||0.3100 - 0.3200|
|52 Week Range||0.1650 - 0.6800|
|Beta (5Y Monthly)||4.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use DENVER, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that it has successfully synthesized
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.